Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
about
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicityExploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responsesModeling chemotherapeutic neurotoxicity with human induced pluripotent stem cell-derived neuronal cellsPopulation pharmacokinetics of peritoneal, plasma ultrafiltrated and protein-bound oxaliplatin concentrations in patients with disseminated peritoneal cancer after intraperitoneal hyperthermic chemoperfusion of oxaliplatin following cytoreductive suMifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy.Reduced proficiency in homologous recombination underlies the high sensitivity of embryonal carcinoma testicular germ cell tumors to Cisplatin and poly (adp-ribose) polymerase inhibition.DNA-bound platinum is the major determinant of cisplatin sensitivity in head and neck squamous carcinoma cells.Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrewsCisplatin and doxorubicin induce distinct mechanisms of ovarian follicle loss; imatinib provides selective protection only against cisplatinIntraperitoneal clearance as a potential biomarker of cisplatin after intraperitoneal perioperative chemotherapy: a population pharmacokinetic studyA method to investigate the anti-metabolic activity of anti-cancer agents on ovarian cancer cells cultured in a 96-well high throughput formatMesenchymal stem cells maintain their defining stem cell characteristics after treatment with cisplatin.Repopulation of ovarian cancer cells after chemotherapyPatient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancerA comprehensive survey of the mutagenic impact of common cancer cytotoxicsNelfinavir is effective against human cervical cancer cells in vivo: a potential treatment modality in resource-limited settings.Therapeutic drug monitoring of cancer chemotherapy.A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis.Moderate renal dysfunction may not require a cisplatin dose reduction: a retrospective study of cancer patients with renal impairment.Efficacy of different sequences of radio- and chemotherapy in experimental models of human melanoma.Pharmacokinetic interaction between pazopanib and cisplatin regimen.Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation Delivery.Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.Resveratrol attenuates cisplatin renal cortical cytotoxicity by modifying oxidative stress.Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells.Optimization of cisplatin doses in a testicular cancer patient with acute renal failure.Estimation of body surface area in the musk shrew ( Suncus murinus): a small animal for testing chemotherapy-induced emesis.Chemotherapy drugs cyclophosphamide, cisplatin and doxorubicin induce germ cell loss in an in vitro model of the prepubertal testis.Influence of selected anti-cancer drugs on the induction of DNA double-strand breaks and changes in gene expression in human hepatoma HepG2 cells.Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors.Cisplatin-based chronotherapy for advanced non-small cell lung cancer patients: a randomized controlled study and its pharmacokinetics analysis.Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.Application of stem cell derived neuronal cells to evaluate neurotoxic chemotherapy.Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.Folding Kinetics of Single Human Telomeric G-Quadruplex Affected by CisplatinNanoSIMS combined with fluorescence microscopy as a tool for subcellular imaging of isotopically labeled platinum-based anticancer drugsInsonation of Systemically Delivered Cisplatin-Loaded Microbubbles Significantly Attenuates Nephrotoxicity of Chemotherapy in Experimental Models of Head and Neck Cancer
P2860
Q24547477-E701A324-9F7A-448F-8D05-7E6AA4A5ADC8Q24604495-7F8EC635-0462-417F-A62F-CC4956E8FCACQ27314983-F6994BDF-6A39-4266-8117-3662C48B3EC4Q33416659-C1E2707E-3EC5-4ECD-9E6A-55673DE45925Q34285363-DA5E5246-B9E4-456D-A55A-C0F994A18CC6Q34516867-C10ED125-5871-486C-B296-BDF22B74B4CCQ34684546-9495CBE1-835C-4F60-A7D5-CB98727014E6Q34807270-29D623F3-FD0D-45B6-9583-29FC2741E273Q34905992-85081C95-A8A6-4538-A37B-3CAE5CDA2496Q35739551-A1E45835-63E2-48D1-A6D3-AA1AA91C8F45Q35817502-C0DB2FC4-C175-453B-B5CC-841AC6B7ACA3Q36500869-D928BB60-E13A-4839-A973-7EC56CC18068Q36725453-A91E3DBE-FA46-4308-8E82-678630247FA6Q36866821-2D064C81-5765-43A7-A307-5107E4BF191BQ36886849-D0A3A6AE-0A97-406E-AFF6-7A99BF7ABE6CQ36981226-012D9CF6-EC04-4D6E-85FA-E856B3C64EA5Q37018328-EEE1AD24-9BD2-4791-8861-ABE4410DA686Q37387427-C346102C-DD6A-49BD-9BEF-6F9A9C9C86FAQ38051037-688997FD-8B84-4D15-8F6E-29855D824935Q39018908-A7E6CC53-8C27-4F2C-9A50-B2F4D423AF75Q40094748-7E56545B-3554-42FD-A3A5-4720D223B895Q41071833-63EAD8F4-3AB4-460C-BA19-F3A17251C845Q41667158-204F2DE4-BE9A-4004-9CFA-6387E551F095Q41956258-6042E355-8732-4586-AF5A-9073F81BC606Q42363687-533FF571-E294-4180-8947-E54CC0535044Q45902992-3F1A0A8A-B377-4622-B4DC-AE41764FAE7EQ47628185-74A96226-95EA-45CB-946E-C0BC9282FCA7Q48147030-66655E06-7FCE-40AD-A4CB-297508DE60D5Q51332973-F286EA8F-6B69-450E-80E4-879AF456F39BQ51515954-E8976882-6673-4587-AD2A-50FC8AF7D8BBQ52935869-EF0719E0-0C10-4BA6-B4D1-AB2A3493FA9DQ53089136-385D048B-10C5-421E-8973-99C05389099AQ53200053-B564E015-232F-444B-9233-205139B6AD84Q54547540-47836A11-3F19-4C96-A7CF-1D1FD1DB1245Q56978022-88D60D32-491D-4848-856D-3DD843688664Q57900979-19AC16AB-E1DF-4691-9372-F62E85276C25Q58762549-551E132A-63FC-415C-8767-EA6BE3F1158C
P2860
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@ast
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@en
type
label
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@ast
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@en
prefLabel
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@ast
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@en
P2860
P1476
Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
@en
P2093
François Lokiec
Sail Urien
P2860
P304
P356
10.1111/J.1365-2125.2004.02082.X
P407
P577
2004-06-01T00:00:00Z